These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31486689)

  • 1. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019).
    Nocentini A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):805-815. PubMed ID: 31486689
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of glaucoma: focus on pharmacological therapy.
    Marquis RE; Whitson JT
    Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure-lowering combination therapies with prostaglandin analogues.
    Aptel F; Chiquet C; Romanet JP
    Drugs; 2012 Jul; 72(10):1355-71. PubMed ID: 22686588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
    Bonardi A; Supuran CT
    Expert Opin Ther Pat; 2019 Oct; 29(10):753-759. PubMed ID: 31438732
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological therapy for glaucoma: a review.
    Hoyng PF; van Beek LM
    Drugs; 2000 Mar; 59(3):411-34. PubMed ID: 10776828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs.
    Tanna AP; Rademaker AW; Stewart WC; Feldman RM
    Arch Ophthalmol; 2010 Jul; 128(7):825-33. PubMed ID: 20625041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
    Tanna AP; Lin AB
    Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel therapies for glaucoma: a patent review (2013-2019).
    Guglielmi P; Carradori S; Campestre C; Poce G
    Expert Opin Ther Pat; 2019 Oct; 29(10):769-780. PubMed ID: 31385719
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
    Lafuma A; Berdeaux G
    Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
    Chew SK; Skalicky SE; Goldberg I
    Expert Opin Pharmacother; 2014 Nov; 15(16):2461-71. PubMed ID: 25267543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pleiotropic effects in local drug treatment for glaucoma].
    Erb C
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):141-5. PubMed ID: 23430678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
    Simmons ST;
    Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapies for glaucoma: a patent review 2007 - 2011.
    Carta F; Supuran CT; Scozzafava A
    Expert Opin Ther Pat; 2012 Jan; 22(1):79-88. PubMed ID: 22191414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glaucoma: a review of adjunctive therapy and new management strategies.
    Whitson JT
    Expert Opin Pharmacother; 2007 Dec; 8(18):3237-49. PubMed ID: 18035966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glaucoma: Current treatment and impact of advanced drug delivery systems.
    Yadav KS; Rajpurohit R; Sharma S
    Life Sci; 2019 Mar; 221():362-376. PubMed ID: 30797820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the discovery of novel agents for the treatment of glaucoma.
    Mincione F; Nocentini A; Supuran CT
    Expert Opin Drug Discov; 2021 Oct; 16(10):1209-1225. PubMed ID: 33914670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ocular hypotensive effect of systemic beta-blockers in patients with primary glaucoma and arterial hypertension].
    Onishchenko AL; Kolbasko AV; Zakharova AV; Onishchenko EG; Zhilina NM
    Vestn Oftalmol; 2017; 133(2):46-51. PubMed ID: 28524139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular Pharmacology.
    Rehovsky J
    Insight; 2016; 41(2):17-21. PubMed ID: 27209686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.